Sir, Faropenem is a new member of the penem class intended for oral administration. Penems share structural similarities with both penicillins and cephalosporins. Preliminary reports indicate that faropenem has a broad spectrum of activity against Gram-positive and -negative bacteria, and is also bactericidal. 1, 2 The purpose of the present study was to evaluate the in vitro activity of faropenem against a large number of recent clinical isolates from various European countries and to compare its activity with that of other orally administered compounds, such as co-amoxiclav, cefuroxime, cefpodoxime, cefdinir, cefixime, ceftibuten and co-trimoxazole. Clarithromycin, telithromycin and ABT-773 were included as comparators for Gram-positive bacteria only, because of their limited antibacterial spectrum.
Against Enterococcus faecalis, faropenem and the remaining comparators were less potent than co-amoxiclav (MIC 50 /MIC 90 1/8 and 1/1 mg/L, respectively) and none of the agents showed activity against Enterococcus faecium.
Faropenem was highly active against group A and B β-haemolytic streptococci and Streptococcus milleri, all strains being inhibited at ≤0.12 mg/L, including those strains exhibiting macrolide resistance (8.6%, 4.9% and 7.9%, respectively, of the isolates tested).
Against viridans streptococci faropenem was very active, all strains being inhibited at 1 mg/L except for those isolates resistant to penicillin.
Faropenem exhibited very good activity against the three major pathogens associated with community-acquired respiratory infections (Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis). Against S. pneumoniae it was the most active agent among the β-lactam antibiotics tested. Although the MICs of faropenem for penicillin-intermediate and -resistant strains were higher than those for penicillin-susceptible strains, 96% of the penicillinresistant strains were inhibited by faropenem at a concentration of 1 mg/L. Among all agents tested, the two ketolide compounds telithromycin and ABT-773 exhibited the highest in vitro activity against all streptococcal isolates.
Against H. influenzae, including β-lactamase-positive strains, the activity of faropenem (MIC 50 /MIC 90 0.5/1 mg/L) was two-fold higher than that of cefuroxime and comparable to that of co-amoxiclav; the third generation cephalosporins were more active than faropenem. At a faropenem concentration of 1 mg/L, 93.7% of the isolates were inhibited. There was no difference in faropenem MIC distribution between β-lactamase-positive and -negative strains.
This new penem was also highly active against all M. catarrhalis isolates (MIC 50 /MIC 90 0.12/0.5 mg/L), including β-lactamase-producing strains. It was two-to eight-fold more active than cefuroxime, cefpodoxime and ceftibuten and was as active as cefixime and cefdinir.
Faropenem showed good activity against Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Citrobacter koseri with MIC 50 s and MIC 90 s of 0.5 and 1-2 mg/L, respectively. Against Proteus spp., Morganella morganii, Providencia spp., Serratia spp. and Enterobacter spp. faropenem exhibited reduced activity (MIC 50 2-8 mg/L and MIC 90 4-32 mg/L). Except for the Proteus spp. faropenem was at least four times more active than co-amoxiclav and cefuroxime against the Enterobacteriaceae tested. In comparison with the third generation cephalosporins tested, faropenem was more active against Citrobacter freundii and Enterobacter spp. and equally as active as cefpodoxime and cefixime against E. coli. Except for C. freundii and Enterobacter spp., ceftibuten was the most active agent against the Enterobacteriaceae.
Neither faropenem nor any of the β-lactam antibiotics tested was active against Pseudomonas aeruginosa and the other non-fermenters.
In summary, our results display a broad spectrum of antibacterial activity of faropenem as shown by others. 1, 4, 5 In particular, faropenem exhibited very good activity against S. pneumoniae, H. influenzae and M. catarrhalis, including penicillin non-susceptible pneumococci and β-lactamaseproducing strains of the latter two species. Its high potency against a variety of common community pathogens recommends faropenem for the treatment of various communityacquired infections, especially those of the respiratory tract.
